Celyad developed a breakthrough Cardiopoiesis platform designed to differentiate stem cells into cardiac cells to treat heart failure and acute myocardial infarction. The lead product, C-Cure® is currently in a Phase III clinical trial, CHART-1, for the treatment of ischemic heart failure in 15 European countries and Israel. The second Phase III clinical trial for this product, CHART-2, will start soon in the United States.